Provention Bio PRVB Stock
Provention Bio Price Chart
Provention Bio PRVB Financial and Trading Overview
Provention Bio stock price | 24.98 USD |
Previous Close | 24.98 USD |
Open | 24.99 USD |
Bid | 25 USD x 38800 |
Ask | 24.99 USD x 301500 |
Day's Range | 24.98 - 25 USD |
52 Week Range | 3.19 - 25 USD |
Volume | 9.12M USD |
Avg. Volume | 2.84M USD |
Market Cap | 2.38B USD |
Beta (5Y Monthly) | 2.460369 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 23.5 USD |
PRVB Valuation Measures
Enterprise Value | 2.17B USD |
Trailing P/E | N/A |
Forward P/E | -192.15385 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 184.21216 |
Price/Book (mrq) | 17.971222 |
Enterprise Value/Revenue | 168.415 |
Enterprise Value/EBITDA | -17.109 |
Trading Information
Provention Bio Stock Price History
Beta (5Y Monthly) | 2.460369 |
52-Week Change | 573.31% |
S&P500 52-Week Change | 19.24% |
52 Week High | 25 USD |
52 Week Low | 3.19 USD |
50-Day Moving Average | 19.1 USD |
200-Day Moving Average | 10.15 USD |
PRVB Share Statistics
Avg. Volume (3 month) | 2.84M USD |
Avg. Daily Volume (10-Days) | 2.5M USD |
Shares Outstanding | 91.1M |
Float | 69.61M |
Short Ratio | 1.53 |
% Held by Insiders | 4.61% |
% Held by Institutions | 53.25% |
Shares Short | 5.88M |
Short % of Float | 7.58% |
Short % of Shares Outstanding | 6.20% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -993.88% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -43.0099% |
Return on Equity (ttm) | -97.65% |
Income Statement
Revenue (ttm) | 12.9M USD |
Revenue Per Share (ttm) | 0.17 USD |
Quarterly Revenue Growth (yoy) | 1408.09% |
Gross Profit (ttm) | -63421000 USD |
EBITDA | -126933000 USD |
Net Income Avi to Common (ttm) | -113565000 USD |
Diluted EPS (ttm) | -1.52 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 165M USD |
Total Cash Per Share (mrq) | 1.74 USD |
Total Debt (mrq) | 24.06M USD |
Total Debt/Equity (mrq) | 19.75 USD |
Current Ratio (mrq) | 1.932 |
Book Value Per Share (mrq) | 1.39 |
Cash Flow Statement
Operating Cash Flow (ttm) | -75408000 USD |
Levered Free Cash Flow (ttm) | 2.87M USD |
Profile of Provention Bio
Country | United States |
State | NJ |
City | Red Bank |
Address | 55 Broad Street |
ZIP | 07701 |
Phone | 908 336 0360 |
Website | https://www.proventionbio.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 174 |
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Q&A For Provention Bio Stock
What is a current PRVB stock price?
Provention Bio PRVB stock price today per share is 24.98 USD.
How to purchase Provention Bio stock?
You can buy PRVB shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Provention Bio?
The stock symbol or ticker of Provention Bio is PRVB.
Which industry does the Provention Bio company belong to?
The Provention Bio industry is Biotechnology.
How many shares does Provention Bio have in circulation?
The max supply of Provention Bio shares is 95.09M.
What is Provention Bio Price to Earnings Ratio (PE Ratio)?
Provention Bio PE Ratio is 0.00000000 now.
What was Provention Bio earnings per share over the trailing 12 months (TTM)?
Provention Bio EPS is 0 USD over the trailing 12 months.
Which sector does the Provention Bio company belong to?
The Provention Bio sector is Healthcare.
Provention Bio PRVB included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16103.45 USD — |
+0.82
|
4.52B USD — | 16094.17 USD — | 16247.59 USD — | — - | 4.52B USD — |
NASDAQ Global Select Market Com NQGS | 7837.41 USD — |
+0.85
|
— — | 7832.7 USD — | 7908.95 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4337.34 USD — |
-0.65
|
— — | 4335.84 USD — | 4376.86 USD — | — - | — — |
NASDAQ HealthCare IXHC | 986.88 USD — |
-0.25
|
— — | 986.44 USD — | 994.67 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4604.4 USD — |
-2.98
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}